Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAF 312 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BAF 312 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects, 18 to 55 years of age included, and in good health * Female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 1 years) * Female subjects ...
BAF 312 is an investigational small molecule being studied for multiple conditions, including relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, hepatic impairment, renal impairment, hemorrhagic stroke, and in healthy volunteers. It is being developed by Novartis AG.
BAF 312 is a small molecule that acts as a sphingosine 1-phosphate receptor modulator. It is being studied for its potential effects on immune cell trafficking in conditions like multiple sclerosis and hemorrhagic stroke.
BAF 312 is being developed by Novartis AG, a global healthcare company traded on the New York Stock Exchange under the ticker NVS. Novartis is conducting clinical trials to evaluate the drug's safety and efficacy across several indications.
BAF 312 is in clinical development. It has completed Phase 1, Phase 2, and Phase 3 trials. The most advanced completed trial was a Phase 3 study in secondary progressive multiple sclerosis, while earlier-phase studies covered hepatic impairment and relapsing-remitting multiple sclerosis.
BAF 312 has been studied in several completed trials. NCT01185821 was a Phase 2 study in relapsing-remitting multiple sclerosis. NCT01565902 was a Phase 1 pharmacokinetic study in hepatic impairment. NCT01665144 was a Phase 3 trial in secondary progressive multiple sclerosis, and NCT03338998 was a Phase 2 study in intracerebral hemorrhage.
Yes, BAF 312 is also known as siponimod. In clinical trials, it has been referred to by both names, including in the EXPAND study for secondary progressive multiple sclerosis, which evaluated siponimod in over 1,600 patients.